

Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over

Information for the public

Published: 7 February 2024

www.nice.org.uk

Nivolumab–relatlimab (Opdualag) is available on the NHS as a possible treatment for untreated advanced melanoma in people 12 years and over. Melanoma is advanced if it has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable).

Nivolumab–relatlimab should be stopped after 2 years, or earlier if the cancer gets worse.

If you are not eligible for nivolumab–relatlimab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on melanoma](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Melanoma Focus](#), 0122 332 4359
- [Melanoma UK](#), 0808 171 2455
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5708-8